ArticleJACC. Case reports2026
Rapid Progression of Coronary Disease in Fabry Disease: Vulnerable Plaque by Intravascular Ultrasound.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMechanisms of rapidly progressive coronary disease in young Fabry patients despite standard therapy remain unclear. CASE SUMMARY: A 43-year-old man with classic Fabry disease developed exertional angina despite receiving enzyme replacement therapy and having well-controlled traditional risk factors. Coronary angiography revealed severe triple-vessel disease, and intravascular ultrasound indicated multiple vulnerable plaques. Positive autoantibodies and elevated C-reactive protein suggested an underlying inflammatory state. Management included percutaneous intervention, intensive lipid-lowering, and the addition of colchicine. DISCUSSION: This case suggests that Fabry disease itself may constitute a strong, independent risk factor for atherosclerosis, and secondary inflammation may further accelerate plaque progression, extending beyond the scope of traditional risk factor assessment. TAKE-HOME MESSAGE: Clinicians should be vigilant for rapid coronary progression in patients with Fabry disease. Intravascular imaging and immune evaluation can help uncover the underlying mechanisms, and comprehensive management might benefit from intensive lipid-lowering and anti-inflammatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.